Biosimilars: Adoption Of Global Reference Comparator Would Eliminate Bridging Studies
Bridging studies conducted between local and foreign versions of the same reference product are redundant, costly and not scientifically necessary for biosimilar development, consultants Christopher Webster and Gillian Woollett write; authors suggest three criteria for global acceptance of a single comparator.
You may also be interested in...
US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.
Sandoz, which used an EU-approved comparator in the switch study for its biosimilar Erelzi, might have to redo the trial in light of FDA’s draft guidance.
US FDA’ s latest ‘n of 1’ guidance describes clinical considerations for INDs to support dosing and monitoring of an individual with a life-threatening genetic disease who is eligible to receive an ASO; recommendations apply only when a few patients may be candidates for treatment.